Latest Financial Results
Q3 2022
Quarter Ended Sep 30, 2022
Stock Information
Symbol
Nasdaq: ZIVOPrice
Change
Volume
52 week Low/High
Day Low/High
Company Overview
ZIVO Bioscience, Inc is dedicated to the development and commercialization of nutritional compounds and bioactive molecules created by its proprietary algal strains. ZIVO is currently in pre-revenue status. The Company is a licensor of internally developed intellectual property in the form of proprietary algae cultures, extracts, derivatives, product and ingredient concepts.
The company is targeting the following applications:
- Human Dietary Supplements & Nutraceuticals | Food Ingredients
- Animal Feed, Dietary Supplements & Drug Development
- Pharmaceuticals for Human Use
Investor Relations
LHA Investor Relations
Tirth T. Patel
Vice President
T: 212-201-6614
tpatel@lhai.com
Transfer Agent
Issuer Direct
1981 Murray Holladay Road
Suite 100
Salt Lake City, UT 84117
T: 801-272-9294
www.issuerdirect.com